This brand name is authorized in Ecuador.
The drug ACROVASTIN AMLO contains a combination of these active pharmaceutical ingredients (APIs):
1
|
UNII
48A5M73Z4Q - ATORVASTATIN CALCIUM TRIHYDRATE
|
|
Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase. Atorvastatin lowers plasma cholesterol and lipoprotein serum concentrations by inhibiting HMG-CoA reductase and subsequently cholesterol biosynthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL. |
|
2
|
UNII
864V2Q084H - AMLODIPINE BESYLATE
|
|
Amlodipine is a calcium ion influx inhibitor of the dihydropyridine group (slow channel blocker or calcium ion antagonist) and inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle. |
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| C10BX03 | Atorvastatin and amlodipine | C Cardiovascular system → C10 Lipid modifying agents → C10B Lipid modifying agents, combinations → C10BX Lipid modifying agents in combination with other drugs |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| EC | Agencia Nacional de Regulación, Control y Vigilancia Sanitaria | 6009-MAN-02-11, 6097-MAN-05-11, 6154-MAN-07-11 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.